Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03720678 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies
A Phase 1 study, sponsored by Arcus Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
NCT03720678 is a Phase 1 study that has completed, run by Arcus Biosciences. The registered enrollment target is 44 participants.
The verdict
NCT03720678, a Phase 1 study, has completed, sponsored by Arcus Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
Study Summary
This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with mFOLFOX in participants with advanced metastatic gastroesophageal Cancer (GEC) or colorectal cancer (CRC).
Interventions
- DRUG mFOLFOX
- DRUG etrumadenant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2018-11-18 |
| Est. Completion | 2021-06-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03720678
The ClinicalTrials.gov registry entry for NCT03720678 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Arcus Biosciences, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which mFOLFOX is the first listed.
NCT03720678 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03720678 about?
NCT03720678 is a clinical study titled "A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies". This is a Phase 1/1b, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of etrumadenant (AB928) in combination with mFOLFOX in participants with advanced metastatic gastroesophageal Cancer (GE...
What is the current status of trial NCT03720678?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2018-11-18. Estimated completion is 2021-06-25.
What interventions are being tested in trial NCT03720678?
The interventions under investigation include: mFOLFOX (DRUG), etrumadenant (DRUG).
Who is sponsoring clinical trial NCT03720678?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.